Respiratorius reports positive preclinical results for VAL001 for the indication relapsing DLBCL
Respiratorius announces that in a new in vitro study, valproate has shown improved inhibitory effects on cell growth, so-called antiproliferative effects, in combination with bendamustine, gemcitabine or carboplatin which are all cytotoxic substances used in the treatment of relapsing diffuse large cell B cell lymphoma (DLBCL). A patent application for the new use of VAL001 has been filed.In newly diagnosed DLBCL, patients are primarily treated with chemotherapy that includes cyclophosphamide,doxorubicin, vincristine and prednisone (CHOP) in combination with immunotherapy, directed against